BMRN · BioMarin Pharmaceutical Inc.

BioMarin’s acquisition of Amicus Therapeutics represents a strategic inflection point, materially expanding its commercial footprint in lysosomal storage diseases through two FDA-approved, globally marketed therapies — Galafold for Fabry disease and the two-component Pombiliti + Opfolda regimen for late-onset Pompe disease. The $4.8 billion all-cash transaction reflects BioMarin’s commitment to diversifying its growth profile beyond its legacy enzyme replacement and gene therapy assets, leveraging its global commercial infrastructure and in-house manufacturing capabilities to accelerate patient access. Critically, the deal also brings DMX-200 — a Phase 3 candidate for FSGS — into BioMarin’s pipeline, marking its first entry into rare nephrology. To fund the acquisition, BioMarin executed a $2.8 billion senior secured credit facility, significantly increasing its debt load with tiered maturities (five-year for Term A and Revolving, seven-year for Term B) and covenant-driven discipline, including mandatory leverage and interest coverage tests. The financing structure — combined with the release of $850 million in escrowed 2034 Notes and existing cash — underscores disciplined capital allocation despite elevated near-term leverage. Management signaled integration focus and financial recalibration by committing to updated FY 2026 guidance on May 4, implying meaningful near-term impacts on revenue mix, operating expenses, and cash flow generation. Investor attention will center on commercial execution synergy — particularly cross-selling Galafold and Pombiliti + Opfolda across BioMarin’s established rare disease channels — and the pace of DMX-200’s regulatory progression post-acquisition.